Steward Partners Investment Advisory’s Franklin US Large Cap Multifactor Index ETF FLQL Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$93.2M Sell
1,190,339
-38,149
-3% -$2.87M 0.48% 34
2026
Q1
$83.1M Buy
1,228,488
+62,095
+5% +$4.36M 0.42% 42
2025
Q4
$80.9M Buy
1,166,393
+99,657
+9% +$6.86M 0.44% 37
2025
Q3
$73M Buy
1,066,736
+45,849
+4% +$3.01M 0.42% 40
2025
Q2
$64.5M Buy
1,020,887
+64,203
+7% +$3.73M 0.5% 30
2025
Q1
$54M Buy
956,684
+70,203
+8% +$4.17M 0.48% 37
2024
Q4
$52M Buy
886,481
+7,452
+0.8% +$442K 0.46% 36
2024
Q3
$51.1M Sell
879,029
-13,392
-2% -$752K 0.47% 39
2024
Q2
$49.6M Sell
892,421
-4,570
-0.5% -$243K 0.52% 33
2024
Q1
$47.8M Buy
+896,991
New +$45.4M 0.53% 34

Other funds holding FLQL

Steward Partners Investment Advisory's FLQL Position: Q2 2026 in Review

Steward Partners Investment Advisory reduced its Franklin US Large Cap Multifactor Index ETF (FLQL) stake by 3.1% in Q2 2026, selling an estimated $2.87M and leaving 1,190,339 shares worth $93.2M. The position accounts for 0.48% of the portfolio, ranked #34.

Steward Partners Investment Advisory first reported a position in FLQL in Q1 2024 and has held it in 10 quarters since. 99 funds tracked by Wall St. Rank hold FLQL as of Q2 2026.

  • Steward Partners Investment Advisory held 1,190,339 shares of Franklin US Large Cap Multifactor Index ETF worth $93.2M as of Q2 2026.
  • Steward Partners Investment Advisory sold 38,149 Franklin US Large Cap Multifactor Index ETF shares in Q2 2026, an estimated $2.87M.
  • Franklin US Large Cap Multifactor Index ETF made up 0.48% of Steward Partners Investment Advisory's portfolio in Q2 2026, its #34 holding.
  • Steward Partners Investment Advisory first reported a position in Franklin US Large Cap Multifactor Index ETF in Q1 2024 and has held it in 10 quarters since.
  • 99 funds tracked by Wall St. Rank held Franklin US Large Cap Multifactor Index ETF as of Q2 2026.

Based on Steward Partners Investment Advisory's 13F filing for Q2 2026, filed 13 Aug 2026.